Cefazolin
- Generic Name
- Cefazolin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14N8O4S3
- CAS Number
- 25953-19-9
- Unique Ingredient Identifier
- IHS69L0Y4T
- Background
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
- Indication
Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylax...
- Associated Conditions
- Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
- Associated Therapies
- Antibiotic pre-surgical prophylaxis
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 38000
- Registration Number
- NCT06567808
Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.
- Conditions
- Interventions
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 751
- Registration Number
- NCT06402591
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
Antibiotic Prophylaxis in Pediatric Open Fractures
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 800
- Registration Number
- NCT06055712
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 33
- Registration Number
- NCT06030713
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Comparing of Cefazolin Plus Azithromycin Versus Cefazolin in Prevention of Febrile Morbidity After Emergency Cesarean Delivery
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT05647993
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Monash University
- Target Recruit Count
- 9180
- Registration Number
- NCT05447559
- Locations
- 🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
🇦🇺St Vincent's Hospital, Melbourne, Australia
Cefazolin PK Study 3g vs 2g
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Baxter Healthcare Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05309304
- Locations
- 🇺🇸
Baxter Investigational Site, Baltimore, Maryland, United States
Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Registration Number
- NCT05304871
Staphylococcus Aureus Network Adaptive Platform Trial
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- University of Melbourne
- Target Recruit Count
- 8000
- Registration Number
- NCT05137119
- Locations
- 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇨🇦Hôpital Régional de Saint Jérôme, Saint-Jérôme, Quebec, Canada
🇳🇱Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIC Cutaneous Melanoma AJCC v8Pathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8Clinical Stage II Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04875728
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.